# Dynamic biomarkers in hormone receptor-positive/HER2-negative breast cancer trials: a new hope for precision oncology

## TL;DR

The paper explores dynamic biomarkers for hormone receptor-positive/HER2-negative breast cancer to improve precision oncology and clinical trial design.

## Contribution

The paper introduces a new framework for using dynamic biomarkers to adaptively guide treatment and transform clinical trial approaches.

## Key findings

- Dynamic biomarkers from tissue and liquid biopsies can track tumor evolution during treatment.
- Metabolic imaging and microbiome profiling offer insights into host-related changes over time.
- A cultural shift in clinical trial design is needed to transition from reactive to proactive oncology.

## Abstract

Hormone receptor-positive/HER2-negative breast cancer evolves in response to therapy, demanding smarter, adaptive biomarker-based treatment strategies. We review emerging dynamic biomarkers to guide therapeutic decision-making, spanning tissue and liquid biopsies, metabolic imaging, and microbiome profiling, that capture tumor or host-related changes over time. By contrasting Academic and Industry approaches, we advocate for a cultural shift in clinical trial design and implementation, aiming to move from reactive to proactive Oncology.